The final day of earnings season has seen a number of ASX 200 shares release their latest results.
Some of these results have gone down well with investors and some have been received less enthusiastically.
Three ASX 200 shares that are making big moves on their results releases are named below. Here's what they reported:
Image source: Getty Images
NextDC Ltd (ASX: NXT)
The NextDC share price has taken a tumble and is down 4% to $9.60. This morning, the data centre operator reported a 10% increase in half-year data centre services revenue to $159.7 million and a 15% lift in underlying earnings before interest, tax, depreciation and amortisation (EBITDA) to a record of $97.5 million.
Looking ahead, the company believes it is well-placed to achieve its FY 2023 guidance. Management expects to hit the top end of its revenue guidance of $340 million to $355 million, with underlying EBITDA in the range of $190 million to $198 million.
Nickel Industries Ltd (ASX: NIC)
The Nickel Industries share price is up 3% to 98.7 cents. This follows the release of the nickel producer's full-year results. Nickel Industries reported an 88.4% increase in revenue to US$1,217 million and a 15.3% lift in net profit to US$159 million.
This was underpinned by a record performance from the company's RKEF operations, which was matched by an equally strong contribution from the Hengjaya Mine. Pleasingly, management expects its strong performance to continue in FY 2023. This is thanks partly to the completion of the haul road from Hengjaya Mine to the Indonesia Morowali Industrial Park.
Telix Pharmaceuticals Ltd (ASX: TLX)
The Telix share price is up 3% to $6.78. Investors have been buying this radiopharmaceutical company's shares after it reported a big jump in revenue in FY 2022. Telix posted group revenue of $160.1 million, up 20 times on FY 2021's $7.6 million. This was driven by the commercial launch of the Illucix product.
And while Telix reported a loss after tax of $104.1 million due to a period of investment to scale-up commercial and clinical activities, it currently has a cash balance of $175 million and a pathway to positive cash flow.
